Drug intelligence / Profile preview

brompheniramine + dextromethorphan + phenylephrine

Development stage: Unknown
Lead developer: Strides Pharma Science
Modality: Small Molecules
Administration: Oral

Overview

Brompheniramine + dextromethorphan + phenylephrine is an oral small molecule combination drug developed by Strides Pharma Science. It is indicated for the treatment of symptoms associated with the common cold, allergy, and cough. Brompheniramine acts as a Histamine H1 receptor antagonist, providing antihistaminic effects. Dextromethorphan functions as an NMDA receptor antagonist and Sigma-1 receptor agonist, serving as a cough suppressant. Phenylephrine is an Alpha-1 adrenergic receptor agonist, which acts as a nasal decongestant.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on brompheniramine + dextromethorphan + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on brompheniramine + dextromethorphan + phenylephrine.

Explore the full profile